Viral Vectors
AAV, AdV, and lentivirus evaluation with biodistribution and immunogenicity profiling.
Modality
Gene & Cell Therapies
We support the preclinical development of your gene and cell therapeutics through professionally conducted in vitro and in vivo efficacy studies. Our experienced team works with all major modalities, including viral vectors (such as AAV, AdV and lentivirus), non-viral gene transfer platforms (including LNPs and polymer nanoparticles), mRNA therapeutics and cell-based therapies, while maintaining strict animal welfare standards.
Customized in vivo Models
We establish and execute a wide range of customized efficacy models in mice and other relevant rodent models, tailored exactly to your therapeutic approach. From specialized disease and tumor models to humanized mouse models, your study design is seamlessly and robustly implemented.
Application Routes
We routinely utilize a broad spectrum of administration routes, including i.p., i.v., intradermal, intramuscular, intranasal, intrathecal, intra-tumoral, s.c. (subcutaneous) and topical/transdermal. The route is selected according to your test item and study objective.
Advanced Monitoring & Biodistribution Analytics
We perform comprehensive post-administration tracking and multi-organ sampling to deeply assess safety and efficacy profiles. Our analytical workflows include the evaluation of viral shedding, therapeutic gene (transgene) expression, tissue biodistribution (via qPCR/ddPCR), vector immunogenicity, and detailed profiling of cytokine levels to evaluate potential immune responses or cytokine release syndrome risks.
Non-Invasive in vivo Tracking
We leverage state-of-the-art Bioluminescence Imaging to monitor the dynamic distribution of your advanced therapeutics in real time. By utilizing luciferase reporter genes, Bioluminescence Imaging allows for the non-invasive, longitudinal tracking of cell migration, engraftment (e.g., CAR-T cells or stem cells), and viral vector-mediated gene expression in the same animal over extended periods. This powerful optical imaging technology provides highly quantitative, kinetic data while significantly reducing the number of required animals, directly supporting the 3Rs principle of animal welfare.
Efficient and Rapid Execution
We understand that time is a critical factor in the fast-paced landscape of advanced therapeutics. Within the framework of regulatory approvals, we guarantee a prompt realization of your project. You will benefit from very short lead times from the initial study inquiry to the completion of your gene or cell therapy study.
Platform Coverage
Therapeutic modalities we support
Non-Viral Platforms
LNPs, polymer nanoparticles, and mRNA therapeutics with expression and clearance tracking.
Cell-Based Therapies
CAR-T cells, stem cells, and engineered cell therapies with Biolayer Interferometry-based engraftment monitoring.